Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GRM6 | O15303 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aniline SCHEMBL27334107 | 0.98 | ALDH1A1 (0.54) | ALDH1A1HSD17B10LMNACYP1A2CYP3A4 | |
| Ethyl Acetate SCHEMBL27988644 | 0.86 | ALDH1A1 (0.54) | ALDH1A1HSD17B10LMNACYP1A2CYP3A4 | |
| Ethyl Acetate SCHEMBL28858805 | 0.86 | ALDH1A1 (0.61) | ALDH1A1HSD17B10LMNACYP1A2CYP3A4 | |
| Aniline SCHEMBL27371840 | 0.84 | ALOX15 (0.60) | ALDH1A1HSD17B10LMNACYP1A2CYP3A4 | |
| Ethyl Acetate SCHEMBL28273284 | 0.84 | LMNA (0.58) | ALDH1A1HSD17B10LMNACYP1A2CYP3A4 | |
| Toluene SCHEMBL14353557 | 0.83 | ALDH1A1 (0.61) | ALDH1A1HSD17B10LMNATSHRMEN1 | |
| Toluene SCHEMBL6453722 | 0.83 | ALDH1A1 (0.61) | ALDH1A1HSD17B10LMNATSHRMEN1 | |
| Toluene SCHEMBL15348475 | 0.83 | ALDH1A1 (0.61) | ALDH1A1HSD17B10LMNATSHRMEN1 | |
| Toluene SCHEMBL1405615 | 0.83 | ALDH1A1 (0.61) | ALDH1A1HSD17B10LMNATSHRMEN1 | |
| Toluene SCHEMBL21490912 | 0.83 | ALDH1A1 (0.61) | ALDH1A1HSD17B10LMNATSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7291645-B2 | Phenylalanine derivatives as alpha 4 integrin inhibitors | ELAN PHARMACEUTICALS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-7208598-B2 | Derivatives of purine, their preparation process and pharmaceutical compositions containing them | AVENTIS PHARMA (FR) | 2007-04-24 | — | — | US | disclosed |
| US-7122669-B1 | Purine derivatives, preparation method and pharmaceutical compositions containing same | HOECHST MARION ROUSSEL (FR) | 2006-10-17 | — | — | US | disclosed |
| US-7015216-B2 | Heteroaryl-β-alanine derivatives as alpha 4 integrin inhibitors | ELAN PHARMACEUTICALS, INC. (US) | 2006-03-21 | — | — | US | disclosed |
| US-20050187228-A1 | Derivatives of purine, their preparation process and pharmaceutical compositions containing them | AVENTIS PHARMA S.A. | 2005-08-25 | — | — | US | disclosed |
| US-20040127486-A1 | Phenylalanine derivatives as alpha 4 integrin inhibitors | ELAN PHARMACEUTICALS, INC. | 2004-07-01 | — | — | US | disclosed |
| US-6689781-B2 | TREATING AN INFLAMMATORY CONDITION IN A MAMMALIAN PATIENT WHICH CONDITION IS MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. | 2004-02-10 | — | — | US | disclosed |
| US-6677339-B2 | S-3-(4-(3,5-DICHLOROPYRID-4-YLCARBOXAMIDO)PHENYL)-2-(4,6-DIMET HOXY-1,3,5-TRIAZIN-2-YLAMINO)PROPANOIC ACID FOR EXAMPLE; INHIBIT BINDING OF ALPHA 4 INTEGRINS TO THEIR LIGANDS, FOR TREATING IMMUNE OR INFLAMMATORY DISORDERS | CELLTECH R & D LIMITED (GB) | 2004-01-13 | — | — | US | disclosed |
| US-20020086882-A1 | Heteroaryl-beta-alanine derivatives as alpha 4 integrin inhibitors | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2002-07-04 | — | — | US | disclosed |
| US-20020055509-A1 | Phenylalanine derivatives as alpha 4 integrin inhibitors | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2002-05-09 | — | — | US | disclosed |
| WO-2002008222-A2 | HETEROARYL-β-ALANINE DERIVATIVES AS ALPHA 4 INTEGRIN INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2002-01-31 | — | — | WO | disclosed |
| WO-2002008206-A1 | 3-AMINO-2-(4-AMINOCARBONYLOXY)PHENYL-PROPIONIC ACID DERIVATIVES AS ALPHA-4- INTEGRIN INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2002-01-31 | — | — | WO | disclosed |
| US-6294293-B1 | Polymer electrical storage device | KT HOLDINGS, LLC | 2001-09-25 | — | — | US | disclosed |
| EP-1117657-A1 | PHENYLALANINE DERIVATIVES AS ALPHA 4 INTEGRIN INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 2001-07-25 | — | — | EP | disclosed |
| EP-0721944-B1 | IMIDAZOLIDINE DERIVATIVE AND USE THEREOF | SUNTORY LTD (JP) | 2001-01-17 | — | — | EP | disclosed |
| WO-2000018759-A1 | PHENYLALANINE DERIVATIVES AS ALPHA 4 INTEGRIN INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 2000-04-06 | — | — | WO | disclosed |
| EP-0853823-A1 | POLYMERIC ELECTRICAL STORAGE DEVICE | Katoot, Mohammed W. (US) | 1998-07-22 | — | — | EP | disclosed |
| US-5691335-A | CARDIOVASCULAR DISORDERS | SUNTORY LIMITED (JP) | 1997-11-25 | — | — | US | disclosed |
| WO-1997013286-A1 | POLYMERIC ELECTRICAL STORAGE DEVICE | KATOOT MOHAMMAD W (US) | 1997-04-10 | — | — | WO | disclosed |
| EP-0721944-A1 | IMIDAZOLIDINE DERIVATIVE AND USE THEREOF | SUNTORY LIMITED (JP) | 1996-07-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055509-A1 | Phenylalanine derivatives as alpha 4 integrin inhibitors | ITGB4, ITGA4, ITGB3 | ALDH1A1 1200/4885HSD17B10 4319/4885LMNA 2515/4885 |
| US-20020086882-A1 | Heteroaryl-beta-alanine derivatives as alpha 4 integrin inhibitors | ITGAL, ITGB4, ITGA4 | ALDH1A1 593/4885HSD17B10 2565/4885LMNA 1126/4885 |
| US-20050187228-A1 | Derivatives of purine, their preparation process and pharmaceutical compositions containing them | CDK6, CDK1, CDK2 | ALDH1A1 2910/4885HSD17B10 4593/4885LMNA 1118/4885 |
| US-20040127486-A1 | Phenylalanine derivatives as alpha 4 integrin inhibitors | ITGB4, ITGA4, ITGB3 | ALDH1A1 1200/4885HSD17B10 4319/4885LMNA 2515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.